OR-NIKE
Today, more than 28 of the world’s top female footballers joined Nike (NYSE:NKE) in Paris to unveil 14 National Team Collections for this summer’s tournament in France. Record-breaking gymnast Simone Biles, champion fencer Ibtihaj Muhammad, two-time Grand Slam winner Li Na and other elite athletes also joined Nike in highlighting new partnerships to champion women and girls in sport.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190311005652/en/
“We believe this summer can be another turning point for the growth of women’s football,” said NIKE, Inc. Chairman, President and CEO Mark Parker. “And our bigger ambition is for that energy and participation to extend into all sports. Nike’s commitment is to continue our leading support of competitive athletes, invest in the next generation at the grassroots level and deliver more innovative and compelling product design for women.”
At the historic Palais Brongniart, Nike revealed an array of future-forward women’s innovation. Design for the 14 National Team Kits began with gathering detailed input on fit from professional footballers, followed by 4D scanning and motion capture in the Nike Sports Research Lab. Echoing this focus on women’s-specific precision engineering is Nike’s Spring/Summer 2019 high-performance bra collection, which was also on display at the event. Beyond innovations in fit, the National Team Kits reflect Nike’s continued commitment to being the world’s most sustainable sports brand, with each 2019 Nike Kit constructed from at least 12 recycled plastic bottles. Since 2010, Nike has diverted more than 6 billion plastic bottles from landfills through sustainable product design.
At the event, Nike also announced a new three-year partnership with UEFA Women’s Football, building on its support of elite footballers from North America to China, and its support of standout female athletes worldwide. In basketball, Nike is partnering with the WNBA, FIBA and the Chinese Basketball Association to grow the women’s game. Meanwhile, at the collegiate level, Nike is partnering with more than 200 universities across the U.S. to support more than 25,000 top female athletes across multiple sports.
At the grassroots level, Nike is addressing barriers to girls’ participation in sport through new community partnerships and access to products to help girls play with confidence. In Paris, Nike is partnering with Sport dans la Ville to train female coaches and engage girls through sports ranging from football and boxing to tennis and dance. Globally, Nike is collaborating with Women Win and Gurls Talk to support rising female coaches who are inspiring the next generation of girls to be active. And from London to Los Angeles, and Beijing to Buenos Aires, Nike is piloting a program to provide products such as the Nike Pro Hijab and Nike Classic Sports Bra to girls in need through schools and community partners worldwide.
Inspiration for these partnerships comes from female athletes who embody strength, power, and the heart and soul of Nike. Throughout 2019, Nike will honor female champions and changemakers with the next phase of its “Just Do It” campaign, which has inspired millions of athletes to chase their crazy dreams. This year, Nike’s campaign shines a spotlight on women around the world who have broken barriers, revolutionized sport and helped level the playing field for all. Click here to view the newest chapters in Nike’s “Just Do It” film series, launching this year in key cities across the globe.
NIKE, Inc., based near Beaverton, Ore., is the world's leading designer, marketer and distributor of authentic athletic footwear, apparel, equipment and accessories for a wide variety of sports and fitness activities. Wholly-owned NIKE, Inc. subsidiary brands include Converse, which designs, markets and distributes athletic lifestyle footwear, apparel and accessories; and Hurley, which designs, markets and distributes surf and youth lifestyle footwear, apparel and accessories. For more information, Nike’s earnings releases and other financial information are available at http://investors.nike.com . Individuals can also visit http://news.nike.com and follow @Nike.
For more information, including multi-media materials, please visit: http://news.nike.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20190311005652/en/
Contact:
Media Contact Mark Rhodes (503) 532-8877
Investor Contact Nitesh Sharan (503) 532-2828
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom